Neuroleptic treatment of HIV-associated psychosis. HNRC group. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Neuroleptic treatment of HIV-associated psychosis. HNRC group.

Neuropsychopharmacology. 1994 Jul;10(4):223-9. Unique Identifier : AIDSLINE MED/95032514
Sewell DD; Jeste DV; McAdams LA; Bailey A; Harris MJ; Atkinson JH; Chandler JL; McCutchan JA; Grant I; University of California, San Diego.

Abstract: The aim of this rater-blinded randomized study was to evaluate the efficacy and side effects of haloperidol and thioridazine in the treatment of new-onset psychosis in HIV-positive individuals. Participants were 13 men who had no history of psychosis prior to infection with HIV, and whose psychosis was not attributable to delirium or to non-HIV-related organic factors. Participants were evaluated at baseline after at least one month without neuroleptic treatment and then weekly for six weeks of the experimental treatment using several rating scales. The mean daily dose in chlorpromazine equivalents was 124 mg. Both neuroleptics produced modest but significant reduction in overall level of psychosis and in positive symptoms, but not in negative symptoms. All the haloperidol-treated patients developed extrapyramidal side effects and required treatment with anticholinergic medication, whereas three of the five thioridazine-treated patients had noticeable side effects. We make recommendations for the treatment of HIV-associated psychosis with neuroleptics.
Keywords: Adolescence Adult Antipsychotic Agents/ADVERSE EFFECTS/*THERAPEUTIC USE AIDS Dementia Complex/*DRUG THERAPY/PATHOLOGY/PSYCHOLOGY Comparative Study Haloperidol/ADVERSE EFFECTS/THERAPEUTIC USE Human Magnetic Resonance Imaging Male Middle Age Psychiatric Status Rating Scales Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. Thioridazine/ADVERSE EFFECTS/THERAPEUTIC USE CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIALKWDadolescenceadultantipsychoticagents/adverseeffects/KWDtherapeuticuseaidsdementiacomplex/KWDdrugtherapy/pathology/psychologycomparativestudyhaloperidol/adverseeffects/therapeuticusehumanmagneticresonanceimagingmalemiddleagepsychiatricstatusratingscalessupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDsupport,uKWDsKWDgov't,pKWDhKWDsKWDthioridazine/adverseeffects/therapeuticuseclinicaltrialjournalarticlerandomizedcontrolledtrial
950228
M9521036

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .